Sepsis associated acute kidney injury research hub

CLEAR-AKI: A multi-center, randomized, double blinded, placebo-controlled, four arm, parallel-group, dose-finding phase 2b study to investigate the safety and efficacy of TIN816 via a single intravenous infusion in the treatment of participants associated with sepsis- associated acute kidney injury (SA-AKI)

This study is looking into a new medicine, TIN816, for people who have kidney damage caused by sepsis. Researchers want to see if it's safe and helps the kidneys work better. Some people will get the medicine, others a dummy treatment.